Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Amortization of Deferred Charges: 2012-2019

Historic Amortization of Deferred Charges for Akebia Therapeutics (AKBA) over the last 3 years, with Dec 2019 value amounting to -$2.2 million.

  • Akebia Therapeutics' Amortization of Deferred Charges fell 5.37% to -$647,000 in Q1 2020 from the same period last year, while for Mar 2020 it was -$2.3 million, marking a year-over-year change of. This contributed to the annual value of -$2.2 million for FY2019, which is N/A change from last year.
  • Per Akebia Therapeutics' latest filing, its Amortization of Deferred Charges stood at -$2.2 million for FY2019, which was down 27,962.50% from $8,000 recorded in FY2013.
  • In the past 5 years, Akebia Therapeutics' Amortization of Deferred Charges registered a high of -$2.2 million during FY2019, and its lowest value of -$2.2 million during FY2019.
  • Over the past 1 years, Akebia Therapeutics' median Amortization of Deferred Charges value was -$2.2 million (recorded in 2019), while the average stood at -$2.2 million.